Palvella Therapeutics receives Yale-licensed patent for QTORIN pitavastatin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026 7:30 AM EDTYale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP)
DSAP is a serious, rare, premalignant genetic skin disease affecting an estimated more than 50,000 diagnosed patients in the U.S., with no FDA-approved therapies
Palvella plans to initiate a Phase 2 clinical trial of QTORIN pitavastatin in DSAP in the second half of 2026
WAYNE, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the Company) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company... More
